Zoetis Inc. $ZTS Shares Sold by Neville Rodie & Shaw Inc.

Neville Rodie & Shaw Inc. decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 56.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 21,415 shares of the company’s stock after selling 27,980 shares during the quarter. Neville Rodie & Shaw Inc.’s holdings in Zoetis were worth $1,539,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. J. Stern & Co. LLP increased its stake in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares during the last quarter. Norges Bank acquired a new position in shares of Zoetis during the 4th quarter valued at about $734,425,000. Vanguard Group Inc. grew its holdings in shares of Zoetis by 12.9% in the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the period. Ruane Cunniff & Goldfarb L.P. purchased a new stake in shares of Zoetis in the first quarter valued at about $286,660,000. Finally, Van ECK Associates Corp increased its position in Zoetis by 269.0% during the fourth quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock worth $300,340,000 after purchasing an additional 1,740,113 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Activity

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This represents a 13.94% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Paul Bisaro purchased 2,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Stifel Nicolaus lowered their price objective on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research note on Friday, June 26th. Citigroup dropped their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. Finally, TD Cowen cut their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $118.33.

Zoetis Stock Performance

Shares of Zoetis stock opened at $76.08 on Wednesday. The business has a 50-day simple moving average of $76.88 and a 200-day simple moving average of $101.64. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a one year low of $71.47 and a one year high of $160.48. The company has a market cap of $31.90 billion, a PE ratio of 12.62, a P/E/G ratio of 1.20 and a beta of 0.74.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period last year, the business earned $1.48 EPS. The firm’s revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.87 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.